Travere Therapeutics
NEWS
The U.S. public apparently believes that drug prices are too high. At the same time, they seem largely opposed to government efforts to control health care costs, alternately supportive and non-supportive of efforts to eliminate the Affordable Care Act, better known as Obamacare.
Retrophin, Inc. today announced that Stephen Aselage, chief executive officer, will present at the BMO 2018 Prescriptions for Success Healthcare Conference in New York City on Wednesday, December 12, 2018 at 9:20 a.m. ET.
Retrophin, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for a new formulation of Thiola (tiopronin) in the treatment of cystinuria.
Retrophin, Inc. today announced that Stephen Aselage, chief executive officer, will present at the Jefferies 2018 London Healthcare Conference in London, UK on Wednesday, November 14, 2018 at 4:40 p.m. GMT (11:40 a.m. ET).
Pivotal programs enrolling towards first data readout in 2019
Increasing achievement of FSGS partial remission of proteinuria and stable eGFR observed out to 84 weeks in open-label extension
DUET publication highlighted during Best of ASN Journals session at ASN Kidney Week 2018
Retrophin, Inc. today announced it will report third quarter 2018 financial results on Thursday, November 1, 2018 after the close of the U.S. financial markets.
Retrophin, Inc. today announced that it will present new data examining the long-term effects of sparsentan in focal segmental glomerulosclerosis (FSGS), at the American Society of Nephrology (ASN) Kidney Week 2018.
JOBS
IN THE PRESS